ArticlePloS one2026
Enhancing the solubility of puerarin via melt sonocrystallization.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, in order to improve the low solubility and poor oral bioavailability of puerarin, we first applied melt sonocrystallization (MSC) technology to systematically investigate the effects on its solubility and crystallographic properties. We applied MSC to treat puerarin, evaluated its solubilization effect using UV spectroscopy, and characterized it by dissolution rate, optical microscope, powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), Thermogravimetric analysis (TGA) and Fourier transform infrared spectroscopy (FTIR). Following MSC treatment, puerarin exhibited higher solubility and faster dissolution, the product displayed reduced particle size and a tendency to agglomerate. The results of PXRD, DSC, FTIR and TGA showed that the crystal form of MSC treated puerarin transformed into puerarin monohydrate, with a decrease in crystallinity and partial amorphization. The reduction in particle size and amorphization may be the driving forces of the increase in solubility and dissolution. In summary, MSC can significantly improve the solubility and dissolution of puerarin, providing new ideas for enhancing its bioavailability and improving its oral formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.